Clinical Trials
12 trialsNCT05596266 2022-10-27
CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia
Xuanwu Hospital, Beijing
Phase 1 Unknown
NCT05398614 2022-06-01
SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1 Unknown
NCT05277753 2022-03-15
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
Shenzhen Geno-Immune Medical Institute
Phase 1 Unknown
NCT05127135 2021-11-19
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies
Fundamenta Therapeutics, Ltd.
Phase 1 Unknown
NCT04934774 2021-06-22
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
iCell Gene Therapeutics
Phase 1 Unknown
NCT04594135 2021-03-02
CD5CAR-T
iCell Gene Therapeutics
Phase 1 Unknown
NCT04004637 2020-09-28
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1 Unknown
NCT04008394 2019-08-07
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT00004036 2013-12-19
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00023816 2013-09-20
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00324597 2013-09-17
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00562068 2013-08-26
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown